Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Mulpleta Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.04.92

    Mulpleta (lusutrombopag) Coverage Policy

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.04.92 alerts

    Get alerted when Policy 05.04.92 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Mulpleta for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure. Coverage requires applicable preferred-drug and clinical criteria and is subject to exclusions, documentation, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyMulpleta (lusutrombopag) Coverage Policy
    Policy CodePolicy 05.04.92
    Change TypeNo material change
    Effective DateJanuary 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit a pretreatment platelet count below 50 × 10^9/L obtained within 14 days of the request for initial prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30 daysInitial authorization duration
    <50 × 10^9/LRequired platelet count
    7 tablets/14 daysQuantity limit
    Not approvableSame-procedure continuation

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA-approvedCovered indication

    Coverage Criteria

    Preferred Drug Plan Design

    The member must meet BOTH the Preferred Drug Plan Design and the applicable criteria for initial approval or continuation of therapy.

    Preferred drug pathway

    • Alternative failure or intolerance: The member has had an inadequate response to, or an intolerable adverse event with, Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta).
    • Clinical reason to avoid alternatives: The member has a clinical reason to avoid both Alvaiz (eltrombopag choline) and eltrombopag olamine (generic Promacta).
    • Current insured treatment with response: The member is currently receiving the requested product through insurance, excluding samples and manufacturer patient assistance programs, and is experiencing a positive therapeutic outcome.

    Initial Therapy: Thrombocytopenia in Chronic Liver Disease

    Covered for an authorization of 30 days when ALL of the following criteria are met.

    Initial approval for thrombocytopenia in chronic liver disease

    • Platelet count: The member has an untransfused platelet count of less than 50 × 10^9/L obtained within 14 days of the request.<50 × 10^9/L within 14 days
    • Scheduled procedure: The member is scheduled to undergo a procedure.

    Continuation Therapy

    Continuation of therapy is not approvable for the same procedure; a newly scheduled procedure requires all initial authorization criteria.

    Newly scheduled procedure: For a newly scheduled procedure, including requests from new members, the member must meet all initial authorization criteria.

    Continuation beyond the initial approval for the same procedure is not approvable.

    Not Medically Necessary

    Mulpleta is considered not medically necessary when the applicable criteria are not met.

    Criteria failure: The member does not meet the criteria set forth in the policy.

    Non-Formulary Exception

    A non-formulary medication may be covered when the approval criteria AND all of the following criteria are met.

    Non-formulary exception

    • Supported indication: The requested drug is used for an FDA-approved indication or an indication supported in the compendia of current literature, such as AHFS, Micromedex, or current accepted guidelines.

      Diagnostic testing or laboratory results are required when applicable.

    • Dose and quantity: The prescribed dose and quantity fall within FDA-approved labeling or dosing guidelines found in the compendia of current literature.
    • Formulary alternatives unsuitable: All covered formulary alternative drugs on any tier are ineffective, have been ineffective, would not be as effective as the non-formulary drug, or would have adverse effects.

      Documentation must include chart notes or other documentation showing prior treatment failure, the severity of any adverse event, the dosage and duration of prior treatment, or a contraindication to formulary alternatives.

    Coverage is excluded for concomitant use of Mulpleta with another thrombopoietin receptor agonist, including Alvaiz, Doptelet, Promacta, or Nplate; a spleen tyrosine kinase inhibitor, such as Tavalisse; or a Bruton's tyrosine kinase inhibitor, such as Wayrilz.

    Mulpleta is considered not medically necessary for members who do not meet the applicable coverage criteria.

    Initial Therapy Criteria

    Initial Therapy for Thrombocytopenia in Chronic Liver Disease

    Initial approval requires the applicable preferred drug pathway AND all clinical criteria.

    Initial approval

    • Preferred drug pathway

      • Alternative failure or intolerance: The member has had an inadequate response to, or an intolerable adverse event with, Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta).
      • Clinical reason to avoid alternatives: The member has a clinical reason to avoid both Alvaiz (eltrombopag choline) and eltrombopag olamine (generic Promacta).
      • Current insured treatment with response: The member is currently receiving the requested product through insurance, excluding samples and manufacturer patient assistance programs, and is experiencing a positive therapeutic outcome.

    Continuation Criteria

    Continuation Therapy

    Continuation of therapy is defined as use beyond the initial approval for the same procedure and is not approvable.

    New procedure initial criteria: All members, including new members, requesting authorization due to a newly scheduled procedure must meet all initial authorization criteria.

    Continuation beyond the initial approval for the same procedure is not approvable.

    Preferred Drug Requirements

    StepRequirementCoverage
    1Member has had an inadequate response to, or an intolerable adverse event with, Alvaiz (eltrombopag choline) or eltrombopag olamine (generic Promacta).Meets preferred drug plan requirement
    1Member has a clinical reason to avoid both Alvaiz (eltrombopag choline) and eltrombopag olamine (generic Promacta).Meets preferred drug plan requirement
    1Member is currently receiving Mulpleta through insurance, excluding samples and manufacturer patient assistance programs, and is experiencing a positive therapeutic outcome.Meets preferred drug plan requirement

    Quantity Limits

    Quantity Limits
    MedicationMulpleta (lusutrombopag) 3 mg
    Quantity limit7 tablets per 14 days
    Dosing scheduleTake once daily for 7 days
    TimingBegin 8 to 14 days before the scheduled procedure; the procedure should take place 2 to 8 days after the last dose

    Procedures, Billing, and Clinical Thresholds

    Procedures and Billing Codesmixed
    N/ANo procedure or billing codes listed.
    Untransfused Platelet Count
    TestUntransfused platelet count
    ThresholdLess than 50 × 10^9/L
    TimingObtained within 14 days of the request

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization and Initial Approval

    Prior authorization is required for Mulpleta treatment of thrombocytopenia in chronic liver disease. Submit the pretreatment platelet count and documentation that the member is scheduled to undergo a procedure; an initial authorization may be granted for 30 days when criteria are met.

    • Pretreatment platelet count
    • Documentation of the scheduled procedure
    • Initial authorization period: 30 days
    Prior Authorization

    Qualified Prescriber Required

    Mulpleta must be prescribed by, or prescribed in consultation with, a hematologist, hepatologist, or gastroenterologist.

    Clinical Background

    Mulpleta (lusutrombopag) is a thrombopoietin receptor agonist used to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure. The policy aligns coverage with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and published guidelines.

    Policy Definitions

    Continuation of Therapy
    DefinitionUse of Mulpleta beyond the initial approval for the same procedure
    Coverage statusNot approvable
    Newly scheduled procedureAll initial authorization criteria must be met, including for new members
    Non-Formulary Exception
    DefinitionA coverage exception for a drug not included on the applicable formulary drug list
    Supported useThe drug must be used for an FDA-approved indication or an indication supported by current literature compendia
    Dose and quantity
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyMulpleta (lusutrombopag) Coverage Policy
    Policy CodePolicy 05.04.92
    Change TypeNo material change
    Effective DateJanuary 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateNot specified
    Key ActionSubmit a pretreatment platelet count below 50 × 10^9/L obtained within 14 days of the request for initial prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaPreferred Drug RequirementsQuantity LimitsProcedures, Billing, and Clinical ThresholdsProvider Actions and Authorization RequirementsClinical BackgroundPolicy Definitions
  1. Clinical criteria: The member has an untransfused platelet count below 50 × 10^9/L obtained within 14 days of the request and is scheduled to undergo a procedure.<50 × 10^9/L within 14 days; authorization for 30 days
  2. Step Therapy

    Preferred Drug Plan Requirement

    The member must meet the Preferred Drug Plan Design requirement in addition to applicable initial approval or continuation criteria. Initial approval requires one of the following circumstances involving preferred alternatives or current therapy.

    • Inadequate response or an intolerable adverse event with Alvaiz (eltrombopag choline) or generic Promacta (eltrombopag olamine)
    • A clinical reason to avoid Alvaiz and generic Promacta
    • Current treatment with Mulpleta through insurance with a positive therapeutic outcome; samples and manufacturer patient assistance programs do not qualify
    Documentation Required

    Pretreatment Platelet Count Required

    Submit the member’s pretreatment platelet count with the prior authorization request for review.

    • Platelet count must be obtained before treatment
    Documentation Required

    Non-Formulary Exception Documentation

    For a non-formulary exception, provide chart notes or other documentation supporting the requested treatment and the clinical need for Mulpleta over covered formulary alternatives.

    • Document prior treatment failure, if applicable
    • Document the severity of any adverse event
    • Include the dosage and duration of prior treatment
    • Document a contraindication to formulary alternatives, when applicable
    Denial Risk

    Prohibited Concomitant Therapy

    Coverage is excluded when Mulpleta is used concurrently with other thrombopoietin receptor agonists, spleen tyrosine kinase inhibitors, or Bruton’s tyrosine kinase inhibitors.

    • Thrombopoietin receptor agonists include Alvaiz, Doptelet, Promacta, and Nplate
    • Spleen tyrosine kinase inhibitors include Tavalisse
    • Bruton’s tyrosine kinase inhibitors include Wayrilz
    Denial Risk

    Initial Clinical Criteria Required

    Initial approval may be denied when the required clinical criteria are not met. The platelet count must be untransfused, less than 50 × 10⁹/L, and obtained within 14 days of the request, and the member must be scheduled to undergo a procedure.

    • Untransfused platelet count < 50 × 10⁹/L
    • Platelet count obtained within 14 days of the request
    • Member scheduled to undergo a procedure
    Denial Risk

    Continuation Is Not Approppable

    Continuation beyond the initial approval for the same procedure is not approvable. A new request is required for a newly scheduled procedure, and the member must meet all initial authorization criteria, including when the member is newly enrolled.

    • Same-procedure continuation: not approvable
    • Newly scheduled procedure: submit a new initial request
    • Members who do not meet the criteria are considered not medically necessary
    Denial Risk

    Non-Formulary Exception Requirements

    A non-formulary exception may be covered only when the approval criteria are met and all non-formulary requirements are satisfied. Requests may be denied for unsupported indications, dosing outside accepted guidance, or failure to establish that covered formulary alternatives are unsuitable.

    • Use must be for an FDA-approved indication or an indication supported by current compendia or accepted guidelines; submit diagnostic testing or laboratory results when applicable
    • Dose and quantity must fall within FDA-approved labeling or compendia dosing guidelines
    • All covered formulary alternatives on any tier must be ineffective, previously ineffective, less effective, associated with adverse effects, or contraindicated
    • Required supporting documentation must be submitted when applicable
    Must fall within FDA-approved labeling or compendial dosing guidelines
    Formulary alternativesAll covered formulary alternatives must be ineffective, less effective, associated with adverse effects, or contraindicated